INS and cancer: Patients receiving insulin or sulfonylurea had a higher risk of all cancers, compared to those receiving metformin (OR: 1.583, 95% CI: 1.389–1.805, P < 0.001 and OR: 1.784, 95% CI: 1.406–2.262, P < 0.001, resp).